Solexa

Solexa
Name	Solexa
Founded	1998
Founders	Shankar Balasubramanian, David Klenerman
Fate	Acquired by Illumina, Inc. (2007)
Headquarters	Cambridge, England
Industry	Biotechnology
Products	DNA sequencing technology, sequencing platforms

Solexa

Solexa was a biotechnology company founded in Cambridge, England by Shankar Balasubramanian and David Klenerman that developed a novel DNA sequencing platform later acquired by Illumina, Inc.. The company’s technology interfaced with innovations originating at University of Cambridge and influenced projects at institutions such as Wellcome Trust Sanger Institute, Broad Institute, and European Molecular Biology Laboratory. Solexa’s platform reshaped workflows used by National Institutes of Health, Centers for Disease Control and Prevention, and commercial laboratories worldwide.

History

Solexa was established to commercialize sequencing chemistry derived from research at University of Cambridge by Balasubramanian and Klenerman, who had connections to Gurdon Institute and collaborations with groups at Massachusetts Institute of Technology and Harvard University. Early financing involved venture capital from firms linked to Cambridge Science Park and investors with ties to Biotechnology Industry Organization networks. Solexa partnered with diagnostic and academic centers such as Wellcome Trust Sanger Institute, Roche Diagnostics, and research programs at Stanford University to validate technology. The company navigated regulatory, patent, and commercialization pathways involving agencies like European Patent Office and legal proceedings referencing stakeholders such as Life Technologies and Affymetrix. In 2007 Solexa was acquired by Illumina, Inc., a transaction that integrated Solexa chemistry into Illumina’s product line and impacted market dynamics among competitors including Applied Biosystems and Pacific Biosciences.

Technology and Platform

Solexa’s core innovation was a massively parallel sequencing-by-synthesis chemistry developed from work at University of Cambridge laboratories and enabled by optics and fluidics expertise from collaborations with engineering teams at Imperial College London and University of Oxford. The platform combined reversible terminator nucleotides, solid-phase amplification methods related to bridge amplification used in collaborations with EMBL-EBI groups, and imaging systems comparable in instrumentation to devices from Nikon and Olympus Corporation used in microscopy. The technology interfaced with bioinformatics toolchains utilized by groups at Wellcome Trust Sanger Institute, Broad Institute, and National Human Genome Research Institute to process large-scale datasets. Hardware and software design decisions reflected partnerships with manufacturers such as Sony Corporation for optics and firms in Cambridge, Massachusetts and San Diego, California for electronics. Intellectual property filings involved litigations and cross-licensing discussions with companies including Life Technologies, Roche, and Illumina, Inc. prior to acquisition.

Sequencing Workflow

The sequencing workflow developed by Solexa encompassed sample preparation protocols similar to those used in protocols from laboratories at Cold Spring Harbor Laboratory and reagent development informed by suppliers like New England Biolabs. Library preparation employed enzymatic steps and adapter ligation techniques used in studies at Massachusetts General Hospital and sequencing runs were performed using flow cell designs refined through engineering teams with expertise from Cambridge Consultants and WPI-affiliated groups. Cluster generation via bridge amplification on glass slides echoed methods used in high-throughput projects at Wellcome Trust Sanger Institute and Broad Institute. Imaging cycles captured fluorescent signals using cameras and optics comparable to those in instrumentation from Hamamatsu Photonics and processing pipelines adapted algorithms from teams at European Bioinformatics Institute and University of California, Berkeley for base calling and error correction.

Data Output and Analysis

Solexa-generated data produced short-read sequences that required alignment and variant-calling workflows developed at institutions such as Broad Institute, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, University of California, Santa Cruz, and Johns Hopkins University. Bioinformatics tools and formats that arose in the ecosystem—created by groups at Harvard Medical School, Stanford University, and University of California, San Diego—included aligners, assemblers, and variant callers adapted to the platform’s error profiles. Large-scale projects supported by agencies like National Institutes of Health and consortia including 1000 Genomes Project and International Cancer Genome Consortium utilized analytical frameworks from The Cancer Genome Atlas and data repositories operated by European Nucleotide Archive and GenBank. Computational infrastructure and workflows drew on technologies and methods from Amazon Web Services, Google Cloud Platform, and high-performance computing centers at Lawrence Berkeley National Laboratory and Argonne National Laboratory.

Applications

Solexa’s sequencing platform enabled studies across human genetics programs at Wellcome Trust Sanger Institute, Broad Institute, and clinical projects at Mayo Clinic and Cleveland Clinic. Applications included population genomics in projects connected to 1000 Genomes Project, cancer genomics within The Cancer Genome Atlas, microbial surveillance partnered with Centers for Disease Control and Prevention, and metagenomics efforts linked to J. Craig Venter Institute. Translational research at hospitals such as Massachusetts General Hospital and Johns Hopkins Hospital used the platform for diagnostics research and precision medicine studies aligned with initiatives at National Cancer Institute. Agricultural and environmental genomics research groups at USDA and CSIRO also applied the technology for crop and ecosystem studies.

Intellectual Property and Commercialization

Solexa’s commercialization involved patent portfolios filed with the European Patent Office and the United States Patent and Trademark Office, with contested claims examined in proceedings referencing stakeholders including Illumina, Inc., Life Technologies, and Affymetrix. Licensing negotiations and litigation shaped industry standards and influenced acquisitions, notably the 2007 purchase by Illumina, Inc., which integrated Solexa chemistry into Illumina product lines marketed to customers such as Wellcome Trust Sanger Institute and clinical labs affiliated with Mayo Clinic. The transactions affected relationships among major sequencing firms including Applied Biosystems, Pacific Biosciences, and emerging startups spun out of research at University of Cambridge and Stanford University.

Category:Biotechnology companies of the United Kingdom